A fundamental analysis of Sun Pharmaceutical Industries Ltd. (SUNPHARMA) covering revenue trends, profitability, valuation, and shareholding patterns.
Sun Pharma Revenue Trend
For FY2025, Sun Pharmaceutical Industries Ltd. recorded revenue of ₹52,578 Cr. That's 5.5% higher than the ₹49,851 Cr it brought in during FY2024.
Stepping back, the 10-year revenue CAGR of 6.7% shows Sun Pharmaceutical Industries Ltd. has been growing at a moderate, sustainable pace.
Sun Pharmaceutical Industries Ltd.'s ₹52,578 Cr revenue base puts it in the major bracket among pharmaceuticals companies in India.
Sun Pharmaceutical Industries Ltd. has posted revenue growth for 7 consecutive years — that's a sustained trend, not a one-off.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹52,578 Cr | +5.5% |
| FY2024 | ₹49,851 Cr | +13.6% |
| FY2023 | ₹43,886 Cr | +13.5% |
| FY2022 | ₹38,654 Cr | +15.4% |
| FY2021 | ₹33,498 Cr | — |
View Sun Pharmaceutical Industries Ltd.'s full 10-year revenue trend with CAGR analysis →
Sun Pharma Profitability
Profitability strengthened with net income of ₹10,929 Cr in FY2025, 13.7% higher than FY2024.
Cost discipline paid off, with net profit margin expanding to 20.8% from 19.3%.
Earnings per share (diluted) were ₹45.60 in FY2025, up from ₹39.90.
Is Sun Pharma Undervalued
The P/E Ratio model estimates an intrinsic value of ₹1,989, implying a 11.2% upside from the current price.
Sun Pharmaceutical Industries Ltd. shares are currently trading at ₹1,788.50.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹1,989 | 11.2% upside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Sun Pharmaceutical Industries Ltd. with detailed assumptions →
Sun Pharma Shareholding Pattern
A stable promoter holding of 54.5% over 4 quarters suggests the management group is comfortable with its position.
FII ownership stands at 15.9%, down from the 17.3% recorded a year ago.
Domestic investors held 21.1% of the company as of March 2026, up year-over-year from 19.5%.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 54.5% | 15.9% | 21.1% | 8.5% |
| Dec 2025 | 54.5% | 16.1% | 20.8% | 8.6% |
| Sep 2025 | 54.5% | 16.6% | 20.2% | 8.7% |
| Jun 2025 | 54.5% | 17.3% | 19.5% | 8.8% |
Track quarterly shareholding changes for Sun Pharmaceutical Industries Ltd. →
Sun Pharma Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
In FY2025, the total asset base came in at ₹921.01B, up 7.8% YoY from ₹854.63B.
Cash & ST Investments accounts for 27.1% of the total, ahead of Intangibles & Goodwill (19.5%) and Receivables (14.2%).
Capital structure: 78.7% equity, 2.6% debt, 18.7% operating liabilities. Over the year, debt is down 27.8% and equity is up 8.0%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 249.88B |
| Receivables | 130.46B |
| Inventories | 102.43B |
| Property, Plant & Equipment | 112.70B |
| Investments | 46.98B |
| Intangibles & Goodwill | 179.60B |
| Other Assets | 98.95B |
| Category | Value |
|---|---|
| Equity | 724.86B |
| Short-term Debt | 20.04B |
| Long-term Debt | 3.58B |
| Trade Payables | 61.84B |
| Other Liabilities | 110.69B |
Sun Pharma at a Glance
Here's the bottom line on Sun Pharmaceutical Industries Ltd. (SUNPHARMA) based on the latest available financials.
Revenue of ₹52,578 Cr in FY2025, up 5.5% year-over-year.
Long-term revenue has been compounding at 6.7% annually over 10 years.
The company is profitable, with a net margin of 20.8% and net income of ₹10,929 Cr.
The P/E Ratio model implies 11.2% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
There's more to the story. Craytheon's full profile for Sun Pharmaceutical Industries Ltd. includes three valuation models, decade-long financials, and insider activity.